Retour

Harmony Biosciences Holdings, Inc.

Qualité des données : 100%

HRMY

NASDAQ Healthcare Biotechnology

27,60 €

▼ 0,12 € (-0,43%)

Cap. Boursière : 1,60B

Fourchette du Jour

27,55 € 28,49 €

Fourchette 52 Semaines

25,52 € 40,87 €

Volume

706 097

Moyenne 50J / 200J

33,21 € / 33,59 €

Clôture Précédente

27,72 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique	Action	Médiane du Secteur
P/E	10,1	0,4
P/B	1,8	2,9
ROE %	20,8	3,7
Net Margin %	18,3	3,9
Rev Growth 5Y %	29,9	10,0
D/E	0,3	0,2

Objectif de Cours des Analystes

Hold

48,17 € +74.5%

Low: 31,00 € High: 62,00 €

P/E Prévisionnel

7,8

BPA Prévisionnel

3,55 €

Croissance BPA (est.)

+0,0%

CA Est.

1 B

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2030	4,53 € 3,88 € – 4,95 €	1,1 B	3
FY2029	5,17 € 4,43 € – 5,65 €	1,3 B	3
FY2028	4,87 € 1,45 € – 6,48 €	1,2 B	9

Points Clés

Revenue grew 29,85% annually over 5 years — strong growth

ROE of 20,75% indicates high profitability

Net margin of 18,27% shows strong profitability

Debt/Equity of 0,28 — conservative balance sheet

Generating 347,89M in free cash flow

P/E of 10,06 — trading at a low valuation

Croissance

Revenue Growth (5Y)

29,85%

Revenue (1Y)21,51%

Earnings (1Y)9,07%

FCF Growth (3Y)26,02%

Qualité

Return on Equity

20,75%

ROIC14,09%

Net Margin18,27%

Op. Margin24,00%

Sécurité

Debt / Equity

0,28

Current Ratio3,60

Interest Coverage14,23

Valorisation

P/E Ratio

10,06

P/B Ratio1,83

EV/EBITDA5,20

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	21,51%	Revenue Growth (3Y)	22,15%
Earnings Growth (1Y)	9,07%	Earnings Growth (3Y)	10,97%
Revenue Growth (5Y)	29,85%	Earnings Growth (5Y)	46,34%
Profitability
Revenue (TTM)	868,45M	Net Income (TTM)	158,69M
ROE	20,75%	ROA	12,48%
Gross Margin	77,16%	Operating Margin	24,00%
Net Margin	18,27%	Free Cash Flow (TTM)	347,89M
ROIC	14,09%	FCF Growth (3Y)	26,02%
Safety
Debt / Equity	0,28	Current Ratio	3,60
Interest Coverage	14,23	Dividend Yield	0,00%
Valuation
P/E Ratio	10,06	P/B Ratio	1,83
P/S Ratio	1,84	PEG Ratio	1,74
EV/EBITDA	5,20	Dividend Yield	0,00%
Market Cap	1,60B	Enterprise Value	1,08B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	868,45M	714,73M	582,02M	437,86M	305,44M
Net Income	158,69M	145,49M	128,85M	181,47M	34,60M
EPS (Diluted)	2,71	2,51	2,13	2,97	0,58
Gross Profit	670,11M	557,92M	460,79M	354,37M	249,92M
Operating Income	208,47M	190,83M	192,03M	120,19M	87,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	1,27B	999,20M	811,45M	673,87M	433,44M
Total Liabilities	401,41M	340,05M	344,46M	271,03M	246,94M
Shareholders' Equity	870,22M	659,16M	466,99M	402,84M	186,51M
Total Debt	239,58M	181,41M	193,57M	191,65M	195,74M
Cash & Equivalents	752,50M	453,00M	311,66M	243,78M	234,31M
Current Assets	907,01M	579,25M	451,07M	400,29M	284,44M
Current Liabilities	252,13M	175,08M	163,78M	78,88M	53,78M

Scores de Stratégies

This stock passed the criteria for 6 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#284 of 1024

Custom Capital Light Compounder

#149 of 213

Custom Contrarian Investing (David Dreman)

#381 of 658

Custom Full Throttle

#97 of 146

Value Value Investing (Warren Buffett)

#13 of 195

Custom Balanced Risk

#61 of 148

Activité Récente

Entré Cash Flow Compounder

Mar 24, 2026

Entré Capital Light Compounder

Mar 24, 2026

Entré Contrarian Investing (David Dreman)

Mar 24, 2026

Entré Value Investing (Warren Buffett)

Mar 24, 2026

Entré Full Throttle

Mar 24, 2026

Entré Balanced Risk

Mar 24, 2026